Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen (NASDAQ:AXGN)

Axogen, Inc. ( AXGN ) managed to deliver some pretty strong Q3 '25 figures back in October. Non-GAAP EPS came in at $0.12, beating expectations by $0.05, and revenue hit $60.1 million, up about 23.7% year-over-year and $3.2 million above theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation ga ...